Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

Asian ethnic bridging study

17 evidence topics · 1 source

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics by ethnic cohort
CharacteristicCohort 1: Japanese (n=8)Cohort 2: Chinese (n=8)Cohort 3: Caucasian (n=8)Overall (n=24)
Age (years), mean (SD)“42.6 (9.3)”“38.4 (8.2)”“45.5 (11.8)”“42.2 (9.9)”
Sex, female/male, n (%)“1 (12.5)/7 (87.5)”“0 (0.0)/8 (100.0)”“5 (62.5)/3 (37.5)”“6 (25.0)/18 (75.0)”
Hispanic or Latino, n (%)“0 (0.0)”“0 (0.0)”“2 (25.0)”“2 (8.3)”
Not Hispanic or Latino, n (%)“8 (100.0)”“8 (100.0)”“6 (75.0)”“22 (91.7)”
Height (cm), mean (SD)“170.2 (8.2)”“170.0 (3.0)”“168.6 (7.7)”“169.6 (6.4)”
Weight (kg), mean (SD)“66.4 (10.2)”“72.6 (9.7)”“80.4 (8.1)”“73.1 (10.7)”
Efficacy results
Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort
ParameterCohort 1: Japanese (n=8)Cohort 2: Chinese (n=8)Cohort 3: Caucasian (n=8)
Cmax,ss (ng/mL), geometric mean (CV%)“502 (25.1)”“586 (24.3)”“531 (11.1)”
AUC0-τ,ss (hr*ng/mL), geometric mean (CV%)“3,410 (22.7)”“4,580 (18.3)”“3,530 (9.5)”
Tmax,ss (hr), median (min, max)“2.8 (2.0, 4.0)”“3.0 (1.0, 6.0)”“1.0 (1.0, 2.0)”
t1/2,ss (hr), geometric mean (CV%)“7.6 (20.4)”“8.4 (13.4)”“9.1 (17.0)”
CL/F (L/hr), geometric mean (CV%)“10.8 (22.7)”“8.0 (18.3)”“10.4 (9.5)”
Vd/F (L), geometric mean (CV%)“118.0 (35.9)”“97.4 (26.5)”“138.0 (17.7)”
BWCmax (ng/mL/mg/kg), geometric mean (CV%)“895 (32.5)”“1,140 (14.3)”“1,140 (12.6)”
BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%)“6,080 (26.9)”“8,950 (9.8)”“7,540 (11.4)”
Rac, geometric mean (CV%)“2.10 (96.3)”“2.48 (38.0)”“2.09 (34.7)”
MRCmax main metabolite, geometric mean (CV%)“2.65 (33.6)”“2.91 (23.1)”“2.60 (24.9)”
MRAUC main metabolite, geometric mean (CV%)“3.56 (30.3)”“3.69 (24.9)”“3.73 (15.8)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by dose period and ethnic cohort
Event20 mg, Japanese (n=8)20 mg, Chinese (n=8)40 mg, Japanese (n=8)40 mg, Chinese (n=8)40 mg BID, Japanese (n=8)40 mg BID, Chinese (n=8)40 mg BID, Caucasian (n=8)
Any TEAE, n (%)“1 (12.5)”“2 (25.0)”“5 (62.5)”“1 (12.5)”“4 (50.0)”“5 (62.5)”“6 (75.0)”
At least 1 TEAE Grade 2, n (%)“0 (0.0)”“1 (12.5)”“0 (0.0)”“1 (12.5)”“1 (12.5)”“0 (0.0)”“4 (50.0)”
At least 1 TEAE Grade ≥3, n (%)“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”
TEAE related to study medication“1 (12.5)”“1 (12.5)”“5 (62.5)”“1 (12.5)”“4 (50.0)”“4 (50.0)”“6 (75.0)”
TEAEs leading to study discontinuation“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“1 (12.5)”
TEAEs leading to study medication discontinuation“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“0 (0.0)”“1 (12.5)”
Study limitations
Summary
  • The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
  • The study was single-center and open-label, with 24 healthy participants (8 per cohort).
  • The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
  • Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
  • The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.